RT Journal Article
SR Electronic
A1 Rizzo, Toni
T1 Effects of Prior Bevacizumab Use on Outcomes from the VELOUR Study
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 7
SP NP
OP NP
DO 10.1177/155989771207003
UL http://mdc.sagepub.com/content/12/7/NP.3.abstract
AB In the Phase 3 Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen [VELOUR; NCT00561470] trial, aflibercept plus FOLFIRI improved overall survival (OS) compared with FOLFIRI plus placebo in patients with metastatic colorectal cancer. This subgroup analysis of the VELOUR trial evaluated the consistency of aflibercept's effect on OS and progression-free survival in a prespecified analysis of patients previously treated with bevacizumab.